AR and Hypertension: In a recent systematic review and meta-analysis of RCTs that included patients who received AR axis-targeted therapies for nmCRPC, mCRPC, and mHSPC, enzalutamide was ranked the most toxic regarding hypertension in the settings of nmCRPC and mCRPC (38).